re: distribution happening; ripped HVAD
With a volume of only 45cc, the HVAD is believed to be the smallest full output long term circulatory assist device under development. HeartWare believes the HVAD to be the only device of its type that can be implanted in the space directly surrounding the heart, rather than in the abdomen. This leads to significant potential advantages, particularly in terms of the ease of surgical implantation and consequent patient benefits.
HeartWare believes that HVAD, once approved, will potentially offer patients and their treating physicians important benefits. These include the following:
A shorter, less traumatic surgical implantation procedure leading to:
faster recovery and hospital discharge
less severe post operative complications
Improved quality of life resulting from:
reduced levels of anticoagulation medication
reduced risk of stroke
improved reliability and durability of the device
HTW
heartware limited
